Oxford BioTherapeutics is Pioneering the Discovery of Novel Oncology Targets for Solid Tumours

OBT076 is an antibody-drug conjugate currently in Phase 1b clinical trials. It employs a potential dual mechanism of action, not only directly targeting cancer cells but also re-engaging the patient’s immune system. By depleting immunosuppressive dendritic cells, OBT076 has the potential to reactivate the immune system and promote the induction and activation of T-cells to enhance the anti-tumour response. OBT076 has demonstrated promising monotherapy activity in a Phase 1b trial for patients with advanced solid tumours (NCT04064359). The recommended phase 2 dose has been established, and preliminary clinical data reveal encouraging signs of efficacy. The solid tumour types being investigated include non-small cell lung cancer, gastric cancer, and bladder cancer.